Comparison of the Effects of Kinesio Taping and Compression Bandaging on Edema, Range of Motion, Upper Extremity Function, and Grip Strength in Patients With Breast Cancer-Related Lymphedema
NCT07919093, Not applicable, Enrolling by invitation, Halic University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Comparison of the Effects of Kinesio Taping and Compression Bandaging on Edema, Range of Motion, Upper Extremity Function, and Grip Strength in Patients With Breast Cancer-Related Lymphedema | ClinicalTrials.gov |
| NCT number | NCT07919093 | ClinicalTrials.gov |
| Status | Enrolling by invitation | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 44 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Halic University | ClinicalTrials.gov |
| Conditions | Lymphedema, Lymphedema Arm, Mastectomy | ClinicalTrials.gov |
| Interventions | lymphedema treatment | ClinicalTrials.gov |
| First posted | 2026-11-05 | ClinicalTrials.gov |
| Last updated | 2026-11-12 | ClinicalTrials.gov |
Registered outcomes 5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in Upper Extremity Edema | The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10. | Arm circumference measurement was used as an objective indicator of lymphedema severity. Circumferential measurements were obtained using a non-elastic tape measure at standardized anatomical landmarks along the upper extremity. Measurements were taken at fixed intervals (e.g., every 5 cm) starting from the wrist and progressing proximally toward the elbow and upper arm. Values were recorded in millimeters (mm), with higher circumference values indicating greater edema severity. There is no predefined upper limit for arm circumference; therefore, larger measurements reflect increased fluid accumulation, whereas smaller values indicate reduced edema. To quantify lymphedema, the difference in circumference between the affected and unaffected extremities was calculated at each measurement point. A greater inter-limb difference represents more severe lymphedema, while a reduction in this difference over time indicates clinical improvement. | ClinicalTrials.gov |
| Primary | Change in Pain Intensity | The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10. | The Visual Analog Scale (VAS) is a 10-centimeter horizontal line used to assess pain intensity. Scores range from 0 to 10, where 0 indicates no pain and 10 indicates worst imaginable pain. Higher scores indicate greater pain severity. | ClinicalTrials.gov |
| Primary | Change in Shoulder Range of Motion | The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10. | Joint range of motion (ROM) was assessed to evaluate upper-extremity mobility in individuals with lymphedema. Active ROM measurements were obtained using a standard universal goniometer based on anatomical landmarks. Measurements were recorded in degrees (°) for wrist, elbow, forearm, and shoulder movements. Higher ROM values indicate greater joint mobility and better functional status, whereas lower values reflect movement limitation. As ROM does not have a single fixed maximum value, results were interpreted relative to anatomical normative values and the contralateral limb. A reduction of ≥10° compared with the unaffected side was considered a clinically meaningful limitation, while an increase toward normal values over time was interpreted as a positive treatment response. Each movement was measured three times, and the mean value was used for analysis. ROM assessments were performed at baseline and after each intervention period. | ClinicalTrials.gov |
| Primary | Change in Upper Extremity Function | The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10. | Upper-extremity functioning was assessed using the Disabilities of the Arm, Shoulder and Hand (QuickDASH) Functioning Scale, a self-reported questionnaire designed to evaluate physical function and symptoms related to upper-limb disorders. The QuickDASH consists of 30 items, each scored on a 5-point Likert scale ranging from 1 (no difficulty) to 5 (unable to perform or extreme difficulty). Item scores are combined and transformed into a total score ranging from 0 to 100, where 0 indicates no disability and 100 represents the most severe functional limitation. Higher scores therefore reflect worse upper-extremity functioning and greater disability. A decrease in QuickDASH score over time indicates functional improvement, whereas an increase reflects worsening functional status. The QuickDASH has no absolute clinical cut-off; however, changes of 10-15 points are generally considered clinically meaningful. | ClinicalTrials.gov |
| Primary | Change in Grip Strength | The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10. | Grip strength was assessed using a Jamar hand dynamometer, a widely accepted and reliable instrument for measuring isometric hand grip strength in clinical and research settings. Measurements were recorded in kilograms (kg), with higher values indicating greater muscle strength and better functional capacity, and lower values reflecting reduced grip strength. Participants were seated in a standardized position with the shoulder adducted and neutrally rotated, the elbow flexed at 90 degrees, the forearm in a neutral position, and the wrist positioned between 0-30° extension and 0-15° ulnar deviation. Participants were instructed to squeeze the dynamometer with maximal effort for a few seconds. Each hand was tested three times, with adequate rest between trials to minimize fatigue, and the mean value was used for analysis. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 31
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 8130940 | BACKGROUND | PubMed |
| 8773720 | BACKGROUND | PubMed |
| 9215977 | BACKGROUND | PubMed |
| 10494522 | BACKGROUND | PubMed |
| 11733293 | BACKGROUND | PubMed |
| 12081053 | BACKGROUND | PubMed |
| 15866967 | BACKGROUND | PubMed |
| 16515423 | BACKGROUND | PubMed |
| 16826318 | BACKGROUND | PubMed |
| 18591761 | BACKGROUND | PubMed |
| 19199105 | BACKGROUND | PubMed |
| 19495810 | BACKGROUND | PubMed |
| 20180029 | BACKGROUND | PubMed |
| 22588748 | BACKGROUND | PubMed |
| 22920313 | BACKGROUND | PubMed |
| 23306413 | BACKGROUND | PubMed |
| 23558699 | BACKGROUND | PubMed |
| 24377096 | BACKGROUND | PubMed |
| 25066648 | BACKGROUND | PubMed |
| 26327833 | BACKGROUND | PubMed |
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)